Novavax Raises 2026 Revenue Forecast

The biotech company lifted its full-year adjusted revenue outlook after payments tied to its licensing deals, and its shares rose in premarket trading.

Updated on Nov. 5, 2026 in Healthcare

Novavax raised its 2026 adjusted revenue forecast to $385 million to $415 million, up from $235 million to $275 million previously. Shares rose over 3% to about $11 in premarket trading.

Why it matters

The higher forecast reflects payments tied to Novavax's licensing deals and partnerships, which rely on its protein-based vaccine platform and Matrix-M adjuvant. The company is betting on these partnerships, including a Sanofi agreement, to return to profitability.

Novavax's new 2026 guidance midpoint of $400 million compares with a prior midpoint of $255 million and an analyst average of $380.29 million. The company posted a quarterly net loss of $31 million, down from $202 million in the same quarter a year earlier, but the breakdown of the revised forecast's one-time versus recurring components was not disclosed.

The players

Novavax

Novavax is a Maryland-based biotechnology company that develops protein-based vaccines and the Matrix-M adjuvant used to strengthen immune responses.

Sanofi

Sanofi is a French multinational pharmaceutical company and the licensing partner whose agreement with Novavax is worth at least $1.2 billion.

The details

Novavax said the revised outlook is driven by payments related to its licensing deals and partnerships tied to its protein-based vaccine platform and Matrix-M adjuvant, which boosts the body's immune response to vaccines. The Sanofi licensing agreement is worth at least $1.2 billion, and Novavax has evaluated more than 30 commercialized vaccines globally for Matrix-M use.

2026: Period covered by the raised full-year adjusted revenue forecast.
2027: Sanofi plans a late-stage U.S. trial of its influenza-COVID-19 combination vaccine.
2028: Novavax targets profitability through the Sanofi deal.

Market Landscape

Novavax's reliance on licensing its Matrix-M adjuvant and protein platform, rather than selling finished vaccines alone, places it in a partnership-driven segment of vaccine development. The raised forecast shows that strategy producing near-term revenue as the company works toward profitability through its Sanofi agreement.

For investors, the raised forecast signals that licensing income is becoming a larger share of Novavax's revenue, which may affect how its shares are valued. The extraction does not indicate any direct change to vaccine prices or availability for consumers.

The takeaway

Novavax's outlook depends heavily on partner-driven payments rather than product sales alone. Investors and observers should watch whether the Sanofi trial and milestone payments arrive on the timelines the company has described.

What happens next

Sanofi plans a late-stage U.S. trial of its influenza-COVID-19 combination vaccine in 2027, and Novavax is eligible for a $225 million milestone payment upon U.S. commercial launch.